Novo Nordisk Future Growth
Future criteria checks 3/6
Novo Nordisk is forecast to grow earnings and revenue by 14.4% and 12.9% per annum respectively. EPS is expected to grow by 14.7% per annum. Return on equity is forecast to be 94.5% in 3 years.
Key information
14.4%
Earnings growth rate
14.7%
EPS growth rate
Pharmaceuticals earnings growth | 20.3% |
Revenue growth rate | 12.9% |
Future return on equity | 94.5% |
Analyst coverage | Good |
Last updated | 15 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 403,442 | 148,413 | 119,462 | 162,829 | 21 |
12/31/2025 | 343,304 | 124,807 | 94,089 | 139,559 | 24 |
12/31/2024 | 286,604 | 101,117 | 68,005 | 121,794 | 20 |
9/30/2024 | 270,583 | 94,721 | 67,031 | 118,218 | N/A |
6/30/2024 | 258,003 | 89,898 | 66,027 | 115,334 | N/A |
3/31/2024 | 244,243 | 89,276 | 50,304 | 93,408 | N/A |
12/31/2023 | 232,261 | 83,683 | 70,012 | 108,908 | N/A |
9/30/2023 | 214,490 | 75,312 | 77,825 | 106,458 | N/A |
6/30/2023 | 201,325 | 67,239 | 67,497 | 89,731 | N/A |
3/31/2023 | 188,290 | 61,129 | 67,341 | 85,115 | N/A |
12/31/2022 | 176,954 | 55,525 | 64,134 | 78,887 | N/A |
9/30/2022 | 167,195 | 52,825 | 57,875 | 68,769 | N/A |
6/30/2022 | 157,251 | 50,539 | 57,680 | 66,037 | N/A |
3/31/2022 | 149,027 | 49,344 | 59,665 | 67,331 | N/A |
12/31/2021 | 140,800 | 47,757 | 47,615 | 55,000 | N/A |
9/30/2021 | 134,605 | 46,183 | 40,213 | 58,189 | N/A |
6/30/2021 | 129,910 | 44,362 | 31,814 | 54,188 | N/A |
3/31/2021 | 126,875 | 42,864 | 31,337 | 53,194 | N/A |
12/31/2020 | 126,946 | 42,138 | 29,870 | 51,951 | N/A |
9/30/2020 | 127,225 | 41,537 | 44,800 | 56,944 | N/A |
6/30/2020 | 126,575 | 41,433 | 47,621 | 56,126 | N/A |
3/31/2020 | 126,605 | 40,403 | 36,987 | 46,904 | N/A |
12/31/2019 | 122,021 | 38,951 | 35,551 | 46,782 | N/A |
9/30/2019 | 119,336 | 38,731 | 36,785 | 49,029 | N/A |
6/30/2019 | 116,821 | 37,574 | 31,251 | 43,960 | N/A |
3/31/2019 | 114,192 | 38,322 | 32,202 | 44,691 | N/A |
12/31/2018 | 111,831 | 38,628 | 32,206 | 44,616 | N/A |
9/30/2018 | 110,091 | 38,384 | 31,576 | 43,236 | N/A |
6/30/2018 | 108,943 | 39,117 | N/A | 44,538 | N/A |
3/31/2018 | 110,174 | 38,725 | N/A | 38,885 | N/A |
12/31/2017 | 111,696 | 38,130 | N/A | 41,168 | N/A |
9/30/2017 | 113,276 | 38,576 | N/A | 46,289 | N/A |
6/30/2017 | 114,199 | 38,609 | N/A | 48,557 | N/A |
3/31/2017 | 113,020 | 38,626 | N/A | 52,937 | N/A |
12/31/2016 | 111,780 | 37,925 | N/A | 48,314 | N/A |
9/30/2016 | 111,084 | 37,484 | N/A | 47,280 | N/A |
6/30/2016 | 110,339 | 36,064 | N/A | 44,179 | N/A |
3/31/2016 | 109,939 | 34,439 | N/A | 41,656 | N/A |
12/31/2015 | 107,927 | 34,860 | N/A | 38,287 | N/A |
9/30/2015 | 103,636 | 33,131 | N/A | 35,469 | N/A |
6/30/2015 | 99,093 | 31,248 | N/A | 35,578 | N/A |
3/31/2015 | 93,663 | 29,899 | N/A | 31,729 | N/A |
12/31/2014 | 88,806 | 26,481 | N/A | 31,692 | N/A |
9/30/2014 | 85,919 | 26,005 | N/A | 29,763 | N/A |
6/30/2014 | 84,181 | 25,920 | N/A | 23,783 | N/A |
3/31/2014 | 83,932 | 25,660 | N/A | 22,941 | N/A |
12/31/2013 | 83,572 | 25,184 | N/A | 25,942 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NOV's forecast earnings growth (14.4% per year) is above the savings rate (1%).
Earnings vs Market: NOV's earnings (14.4% per year) are forecast to grow slower than the German market (20.8% per year).
High Growth Earnings: NOV's earnings are forecast to grow, but not significantly.
Revenue vs Market: NOV's revenue (12.9% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: NOV's revenue (12.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NOV's Return on Equity is forecast to be very high in 3 years time (94.5%).